Cardiovascular risk in patients with renal disease: Treating the risk or treating the risk factor?

Nephrology Dialysis Transplantation

Volumn 19, Issue 1, 2004, Pages 23-26

  Rabelink, Ton J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antiplatelet therapy; Blood pressure control; Cardiovascular risk; Folic acid; Lipid lowering treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; CALCIMIMETIC AGENT; CALCIUM; CALCIUM PHOSPHATE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FATTY ACID; FIBRINOGEN RECEPTOR; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; PLACEBO; ROSUVASTATIN; SEVELAMER;

ANEMIA; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CALCIUM METABOLISM; CAPILLARY DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE; MORTALITY; PHOSPHATE METABOLISM; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; STEM CELL; THROMBOCYTE ANOMALY; TREATMENT INDICATION; TREATMENT PLANNING; UREMIA; VITAMIN SUPPLEMENTATION;

ADULT; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FOLIC ACID; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK; RISK FACTORS;

EID: 0346656657     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg421     Document Type: Editorial

References (26)

1. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-152
2. US Renal Data System. 1999 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, April 1999
3. Culleton BF, Larson MG, Wilson PWF, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999: 56: 2214-2219
4. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636
5. Law MR, Wald NJ. Education and debate. Risk factor thresholds: their existence under scrutiny. Br Med J 2002; 324: 1570-1576
6. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 356 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22
7. Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int 2003; 84 [Suppl]: 121-124
8. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch Intern Med 1992; 152: 56-64
9. Chobanian AV, Bakris GL, Black HR et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, The JNC 7 report. JAMA 2003; 289: 2560-2572
10. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097
11. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-1328
12. Vuurmans TJL, Boer WH, Bos WJ, Blankestijn PJ, Koomans HA. Contribution of volume overload and angiotensin II to the increased pulse wave velocity of hemodialysis patients. J Am Soc Nephrol 2002; 13: 177-183
13. de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95
14. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46: 287-296
15. de Vriese AS, Verbeke F, Schrijvers BF, Lameire NH. Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure? Kidney Int 2002; 61: 1199-1209
16. Stroes ES, van Faassen EE, Yo M et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86: 1129-1134
17. Bennett-Richards K, Kattenhorn M, Donald A et al. Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure? Circulation 2002; 105: 1810-1815
18. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 23-33
19. Lonn E, Yusuf S, Dvavik V et al. SECURE investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-925
20. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomized placebo-controlled trial. Lancet 2000; 356: 1213-1218
21. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992-995
22. Amann K, Ritz E. Microvascular disease: the Cinderella of uraemic heart disease. Nephrol Dial Transplant 2000; 15: 1493-1503
23. Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization. Blood 2003; 102: 1340-1346
24. Drüeke TB. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis. Nephrol Dial Transplant 2002; 17 [SuppI 11]: 20-22
25. Manley HJ, McClaran ML, Overbay DK et al. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis 2003; 41: 386-393
26. Volhard F. Die doppelseitigen hamatogenen Niererkrankungen (Bright'sche Krankheit). Springer, Berlin, Germany, 1918; 567